Chris Chen, WuXi Biologics CEO (Photographer: Anthony Kwan/Bloomberg via Getty Images)
August 20, 2024 03:02 PM EDTUpdated 03:38 PM
China
Manufacturing

WuXi Bi­o­log­ics’ ADC spin­out re­ports rev­enue jump de­spite Biose­cure risk

Anna Brown

News Reporter

AD­Cs are so hot that WuXi Bi­o­log­ics’ spe­cial­ist com­pa­ny has so far ap­peared im­mune to the Biose­cure threat as it un­veiled a rise in rev­enues …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times